Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin

Martin Reck; Nick Thatcher; Egbert F. Smit; Paul Lorigan; Ewa Szutowicz-Zielinska; Astra M. Liepa; Katherine B. Winfree; Patrick Peterson; Susan C. Guba; Mark A. Socinski

doi:10.1016/j.lungcan.2012.09.002

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin

Martin Reck, Nick Thatcher, Egbert F. Smit, Paul Lorigan, Ewa Szutowicz-Zielinska, Astra M. Liepa, Katherine B. Winfree, Patrick Peterson, Susan C. Guba, Mark A. Socinski

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Small cell lung cancer (SCLC) is associated with poor prognosis due to its early metastatic potential and lack of improved outcomes with newer cytotoxic agents. Identifying factors associated with clinical outcomes can help clinicians determine which patients are more likely to benefit from therapy. Functional Assessment of Cancer Therapy (FACT) subscales and Eastern Cooperative Oncology Group performance status (ECOG PS) were retrospectively analyzed as prognostic factors for overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage disease (ED)-SCLC. Methods: Using data from a Phase III trial of pemetrexed-carboplatin vs. etoposide-carboplatin, the effect of the prognostic factors on OS and PFS was analyzed via Cox models. The Kaplan-Meier method was used to estimate OS and PFS parameters for the prognostic subgroups (defined by baseline FACT scores and ECOG PS). Results: Patients with higher baseline FACT-General (FACT-G) score (≥median) had significantly higher OS (hazard ratio [HR] = 0.62, P

Original language	English
Pages (from-to)	276-281
Number of pages	5
Journal	Lung Cancer
Volume	78
Issue number	3
DOIs	https://doi.org/10.1016/j.lungcan.2012.09.002
Publication status	Published - Dec 2012

Keywords

Etoposide plus carboplatin
Extensive-stage disease small cell lung cancer (ED-SCLC)
Functional Assessment of Cancer Therapy (FACT) scale
Pemetrexed plus carboplatin
Performance status
Prognostic factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2012.09.002

Fingerprint

Dive into the research topics of 'Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin'. Together they form a unique fingerprint.

Cite this

Reck, M., Thatcher, N., Smit, E. F., Lorigan, P., Szutowicz-Zielinska, E., Liepa, A. M., Winfree, K. B., Peterson, P., Guba, S. C., & Socinski, M. A. (2012). Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Lung Cancer, 78(3), 276-281. https://doi.org/10.1016/j.lungcan.2012.09.002

@article{b2e52771d2de48cf901a0349d5f6a324,

title = "Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin",

abstract = "Background: Small cell lung cancer (SCLC) is associated with poor prognosis due to its early metastatic potential and lack of improved outcomes with newer cytotoxic agents. Identifying factors associated with clinical outcomes can help clinicians determine which patients are more likely to benefit from therapy. Functional Assessment of Cancer Therapy (FACT) subscales and Eastern Cooperative Oncology Group performance status (ECOG PS) were retrospectively analyzed as prognostic factors for overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage disease (ED)-SCLC. Methods: Using data from a Phase III trial of pemetrexed-carboplatin vs. etoposide-carboplatin, the effect of the prognostic factors on OS and PFS was analyzed via Cox models. The Kaplan-Meier method was used to estimate OS and PFS parameters for the prognostic subgroups (defined by baseline FACT scores and ECOG PS). Results: Patients with higher baseline FACT-General (FACT-G) score (≥median) had significantly higher OS (hazard ratio [HR] = 0.62, P",

keywords = "Etoposide plus carboplatin, Extensive-stage disease small cell lung cancer (ED-SCLC), Functional Assessment of Cancer Therapy (FACT) scale, Pemetrexed plus carboplatin, Performance status, Prognostic factors",

author = "Martin Reck and Nick Thatcher and Smit, {Egbert F.} and Paul Lorigan and Ewa Szutowicz-Zielinska and Liepa, {Astra M.} and Winfree, {Katherine B.} and Patrick Peterson and Guba, {Susan C.} and Socinski, {Mark A.}",

year = "2012",

month = dec,

doi = "10.1016/j.lungcan.2012.09.002",

language = "English",

volume = "78",

pages = "276--281",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier BV",

number = "3",

}

Reck, M, Thatcher, N, Smit, EF, Lorigan, P, Szutowicz-Zielinska, E, Liepa, AM, Winfree, KB, Peterson, P, Guba, SC & Socinski, MA 2012, 'Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin', Lung Cancer, vol. 78, no. 3, pp. 276-281. https://doi.org/10.1016/j.lungcan.2012.09.002

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. / Reck, Martin; Thatcher, Nick; Smit, Egbert F. et al.
In: Lung Cancer, Vol. 78, No. 3, 12.2012, p. 276-281.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin

AU - Reck, Martin

AU - Thatcher, Nick

AU - Smit, Egbert F.

AU - Lorigan, Paul

AU - Szutowicz-Zielinska, Ewa

AU - Liepa, Astra M.

AU - Winfree, Katherine B.

AU - Peterson, Patrick

AU - Guba, Susan C.

AU - Socinski, Mark A.

PY - 2012/12

Y1 - 2012/12

N2 - Background: Small cell lung cancer (SCLC) is associated with poor prognosis due to its early metastatic potential and lack of improved outcomes with newer cytotoxic agents. Identifying factors associated with clinical outcomes can help clinicians determine which patients are more likely to benefit from therapy. Functional Assessment of Cancer Therapy (FACT) subscales and Eastern Cooperative Oncology Group performance status (ECOG PS) were retrospectively analyzed as prognostic factors for overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage disease (ED)-SCLC. Methods: Using data from a Phase III trial of pemetrexed-carboplatin vs. etoposide-carboplatin, the effect of the prognostic factors on OS and PFS was analyzed via Cox models. The Kaplan-Meier method was used to estimate OS and PFS parameters for the prognostic subgroups (defined by baseline FACT scores and ECOG PS). Results: Patients with higher baseline FACT-General (FACT-G) score (≥median) had significantly higher OS (hazard ratio [HR] = 0.62, P

AB - Background: Small cell lung cancer (SCLC) is associated with poor prognosis due to its early metastatic potential and lack of improved outcomes with newer cytotoxic agents. Identifying factors associated with clinical outcomes can help clinicians determine which patients are more likely to benefit from therapy. Functional Assessment of Cancer Therapy (FACT) subscales and Eastern Cooperative Oncology Group performance status (ECOG PS) were retrospectively analyzed as prognostic factors for overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage disease (ED)-SCLC. Methods: Using data from a Phase III trial of pemetrexed-carboplatin vs. etoposide-carboplatin, the effect of the prognostic factors on OS and PFS was analyzed via Cox models. The Kaplan-Meier method was used to estimate OS and PFS parameters for the prognostic subgroups (defined by baseline FACT scores and ECOG PS). Results: Patients with higher baseline FACT-General (FACT-G) score (≥median) had significantly higher OS (hazard ratio [HR] = 0.62, P

KW - Etoposide plus carboplatin

KW - Extensive-stage disease small cell lung cancer (ED-SCLC)

KW - Functional Assessment of Cancer Therapy (FACT) scale

KW - Pemetrexed plus carboplatin

KW - Performance status

KW - Prognostic factors

U2 - 10.1016/j.lungcan.2012.09.002

DO - 10.1016/j.lungcan.2012.09.002

M3 - Article

SN - 0169-5002

VL - 78

SP - 276

EP - 281

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -